GlassScriptPhysician profile
Trevor C Austin
NPI 1659509644
$5,002.90
in general payments reported to CMS, 2019-2025
58 companies · $1,695 in 2025
The $1,695 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $450 · 2022: $995 · 2023: $787 · 2024: $1,077 · 2025: $1,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,533 · Education: $25.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,532.87 |
| Education | $25.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $499.53 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Novartis Pharmaceuticals Corporation | $409.02 | 2021-2025 | Kisqali, Piqray |
| E.R. Squibb & Sons, L.L.C. | $328.89 | 2021-2025 | Opdivo, Opdualag |
| Pfizer INC. | $236.59 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $234.39 | 2022-2025 | Lynparza, Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $222.28 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $210.31 | 2023-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Celgene Corporation | $180.10 | 2022-2025 | Reblozyl, Breyanzi, Opdivo |
| Glaxosmithkline, LLC. | $160.49 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Abbvie INC. | $159.09 | 2021-2025 | |
| Genentech USA, INC. | $157.70 | 2022-2025 | Venclexta, Itovebi |
| Astellas Pharma US INC | $143.39 | 2021-2025 | Padcev, Vyloy |
| Daiichi Sankyo INC. | $129.95 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Eisai INC. | $129.39 | 2022-2024 | |
| Amgen INC. | $119.37 | 2021-2023 | Kyprolis, Blincyto |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.